Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 30:8:F1000 Faculty Rev-121.
doi: 10.12688/f1000research.16517.2. eCollection 2019.

Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria

Richard R Watkins  1   2 , David Van Duin  3
Affiliations
Review

Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria

Richard R Watkins et al. F1000Res. .

Abstract

Pneumonia is one of the most common infections worldwide. Morbidity, mortality, and healthcare costs increase substantially when pneumonia is caused by multidrug-resistant Gram-negative bacteria (MDR-GNB). The ongoing spread of antimicrobial resistance has made treating MDR-GNB pneumonia increasingly difficult. Fortunately, there have been some recent additions to our antibiotic armamentarium in the US and Europe for MDR-GNB, along with several agents that are in advanced stages of development. In this article, we review the risk factors for and current management of MDR-GNB pneumonia as well as novel agents with activity against these important and challenging pathogens.

Keywords: Acinetobacter baumannii; Enterobacteriaceae; Pseudomonas aeruginosa; antibiotics.

PubMed Disclaimer

Conflict of interest statement

Competing interests: RRW serves on an advisory board and speakers’ bureau and has received research support from Allergan. DvD serves on advisory boards for Allergan, Achaogen, Shionogi, Tetraphase, Sanofi Pasteur, MedImmune, and Astellas and has received research funding from Steris Inc. and Scynexis.

References

    1. Thorpe KE, Joski P, Johnston KJ: Antibiotic-Resistant Infection Treatment Costs Have Doubled Since 2002, Now Exceeding $2 Billion Annually. Health Aff (Millwood). 2018;37(4):662–9. 10.1377/hlthaff.2017.1153 - DOI - PubMed

    2. F1000 Recommendation

    1. Kalil AC, Metersky ML, Klompas M, et al. : Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61–e111. 10.1093/cid/ciw353 - DOI - PMC - PubMed

    2. F1000 Recommendation

    1. Bassetti M, Welte T, Wunderink RG: Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair? Crit Care. 2016;20:19. 10.1186/s13054-016-1197-5 - DOI - PMC - PubMed
    1. Watkins RR, Deresinski S: Using β-lactam/β-lactamase inhibitors for infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae to slow the emergence of carbapenem-resistant Enterobacteriaceae. Expert Rev Anti Infect Ther. 2017;15(10):893–5. 10.1080/14787210.2017.1380519 - DOI - PubMed
    1. Grundmann H, Glasner C, Albiger B, et al. : Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis. 2017;17(2):153–63. 10.1016/S1473-3099(16)30257-2 - DOI - PubMed

    2. F1000 Recommendation

MeSH terms

LinkOut - more resources